Arvinas to Present at Upcoming Investor Conferences

Arvinas, a clinical-stage biotechnology company, announced that management will participate in fireside chats at two upcoming investor conferences: Wells Fargo Healthcare Conference and Cantor Global Healthcare Conference. The events will be webcast live on the company's website. Arvinas is developing protein degradation therapies using its PROTAC platform for diseases such as breast cancer, non-Hodgkin lymphoma, and neurodegenerative disorders.

Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company focused on developing targeted protein degradation therapies, announced that management will participate in fireside chats at two upcoming investor conferences. The events, scheduled for September 4 and 5, include the Wells Fargo Healthcare Conference and the Cantor Global Healthcare Conference, respectively. Live audio webcasts of both presentations will be accessible through the company's website under the "Events and Presentations" section of the Investors and Media page.

Arvinas is dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. The company's PROTAC (PROteolysis TArgeting Chimera) protein degrader platform aims to harness the body's natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas is currently progressing multiple investigational drugs through clinical development programs, including vepdegestrant, targeting the estrogen receptor for patients with locally advanced or metastatic ER+/HER2- breast cancer; ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma; ARV-102, targeting LRRK2 for neurodegenerative disorders; and ARV-806, targeting KRAS G12D for mutated cancers, including pancreatic and colorectal cancers.

References:
[1] https://www.globenewswire.com/news-release/2025/08/29/3141410/0/en/Arvinas-to-Participate-in-Upcoming-Investor-Conferences.html
[2] https://www.stocktitan.net/news/ARVN/arvinas-to-participate-in-upcoming-investor-n1atndee88b7.html